How Ipilimumab works

IpilimumabIpilimumab) are immune checkpoint inhibitors, and their main mechanism of action is to enhance the activity of the immune system by inhibiting CTLA-4 (cytotoxic T lymphocyte antigen 4). CTLA-4 is a protein that negatively regulates immune response. It can inhibit the activity of T lymphocytes and reduce the immune system's attack on cancer cells. Ipilimumab works by removing the suppression of the immune system by CTLA-4, making it easier for T lymphocytes to attack cancer cells. Ipilimumab is administered through intravenous injection. After entering the blood circulation, it binds to the CTLA-4 protein and prevents the binding of CTLA-4 to its ligands (B7-1 and B7-2). This can enhance the activity of T lymphocytes and improve their ability to recognize and attack cancer cells.